Cefonicid vs. cefoxitin for cesarean section prophylaxis.
A randomized, prospective study compared a long-acting, second-generation cephalosporin, cefonicid (Monocid), with a short-acting, second-generation cephalosporin, cefoxitin (Mefoxin), for cesarean section prophylaxis. One hundred thirty-nine patients were enrolled, with 81 receiving a 1-g intravenous dose of cefonicid after cord clamping and 58 receiving a 2-g dose of intravenous cefoxitin after cord clamping and at 6, 12 and 18 hours postpartum. In those patients receiving cefonicid prophylaxis, endometritis incidence was 17.3% (14 of 81). This finding was not statistically significant (P less than .397) when compared to the 12.1% incidence of endometritis (7 of 58) with cefoxitin. In addition, the febrile morbidity incidence for cefonicid prophylaxis was 23.5% (19 of 81) as compared to 15.5% (9 of 58) for cefoxitin (P less than .25). Because the two drugs appear to be equally efficacious, cefonicid may be the better choice because of its markedly lower cost.
Hartert
R A
RA
Department of Obstetrics and Gynecology, University Hospital of Jacksonville, Florida 32209.
Benrubi
G
G
Thompson
R J
RJ
Nuss
R C
RC
D000328:Adult; D000367:Age Factors; D002435:Cefamandole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015790:Cefonicid; D002440:Cefoxitin / Q000627:therapeutic use*; D002585:Cesarean Section / Q000009:adverse effects*; D004716:Endometritis / Q000191:economics / Q000517:prevention & control*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies; D011897:Random Allocation; D012307:Risk Factors; D012959:Socioeconomic Factors
D002435:Cefamandole; D015790:Cefonicid; D002440:Cefoxitin